FDA: NTI drugs [Regulatives / Guidelines]

posted by jag009  – NJ, 2016-05-16 00:26 (3696 d 14:22 ago) – Posting: # 16312
Views: 5,237

Hi,

Can someone educate me on how FDA chose a value of 0.10 to sigma w0 as the regulatory constant for the scaled reference BE analysis for an NTI drug (see warfarin BE guidance)? I kind of understand why they chose 0.25 for sigma w0 for HVDs but I don't get the reason for NTI. According to the presntation and literature from FDA, 0.1 represents a CV of ~10% :confused:

Thanks
John

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
212 visitors (1 registered, 211 guests [including 11 identified bots]).
Forum time: 14:49 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5